Patents by Inventor Carlos Lamas-Peteira
Carlos Lamas-Peteira has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8778946Abstract: The invention provides certain 3-substituted-6-(pyridinylmethoxy)-pyrrolopyridine compounds, particularly compounds of formula I and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat Parkinsons disease Formula (I).Type: GrantFiled: November 17, 2011Date of Patent: July 15, 2014Assignee: Eli Lilly and CompanyInventors: Carlos Lamas-Peteira, Simon James Richards, Selma Sapmaz, Magnus Wilhelm Walter
-
Publication number: 20130225602Abstract: The invention provides certain 3-substituted-6-(pyridinylmethoxy)-pyrrolopyridine compounds, particularly compounds of formula I and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat Parkinsons disease Formula (I).Type: ApplicationFiled: November 17, 2011Publication date: August 29, 2013Applicant: ELI LILLY AND COMPANYInventors: Carlos Lamas-Peteira, Simon James Richards, Selma Sapmaz, Magnus Wilhelm Walter
-
Patent number: 7595315Abstract: Compounds of the general formula (I) are inhibitors of the reuptake of norepinephrine. As such, they may be useful for the treatment of disorders of the central and/or peripheral nervous system.Type: GrantFiled: December 10, 2004Date of Patent: September 29, 2009Assignee: Eli Lilly and CompanyInventors: Peter Thaddeus Gallagher, Carlos Lamas-Peteira, Francisco Javier Agejas-Chicharro
-
Patent number: 7354920Abstract: Compounds of formula (I) wherein Rx is H; Ry is H or C1-C4 alkyl; each Rz is independently H or C1-C4 alkyl; X represents O; Y represents OH or OR; R is C1-C4 alkyl; and Ar1 and Ar2 are optionally substituted phenyl or 5- or 6-membered heteroaryl rings are selective inhibitors of the reuptake of norepinephrine.Type: GrantFiled: August 18, 2003Date of Patent: April 8, 2008Assignee: Eli Lilly and CompanyInventors: Manuel Javier Cases-Thomas, Helen Louise Haughton, Robin George Simmonds, Hélène Catherine Eugénie Rudyk, Magnus Wilhelm Walter, Sivi Ouwerkerk-Mahadevan, John Joseph Masters, Carlos Lamas-Peteira
-
Patent number: 7335660Abstract: This invention relates to compounds of formula (I) where R1 to R12, —W—V—, —X—Y—, p and n have the values defined in claim 1, their preparation and use as pharmaceuticals for the treatment of central nervous system disorders, such as depression, bipolar disorder, and anxiety.Type: GrantFiled: December 6, 2002Date of Patent: February 26, 2008Assignee: Eli Lilly and CompanyInventors: Javier Agejas-Chicharro, Graham Henry Timms, Andrew Caerwyn Williams, Nicholas Paul Camp, Jeremy Gilmore, Ana Belen Bueno Melendo, Carlos Lamas-Peteira
-
Publication number: 20070276138Abstract: Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, —CH2— or —CH2CH2—; W is a substituted or unsubstituted alkylene or a substituted or unsubstituted heteroalkylene linking group from two to ten atoms in length, preferably from two to seven atoms in length. Phenyl Ring A is optionally substituted with up to four substituents in addition to R1 and W. R1 is —(CH2)n—CH(OR2)—(CH2)mE, —(CH)?C(OR2)—(CH2)mE, —(CH2)n—CH(Y)—(CH2)mE or —(CH)?C(Y)—(CH2)mE; wherein E is COOR3, C1-C3-alkylnitrile, carboxamide, sulfonamide, acylsulfonamide or tetrazole and wherein sulfonamide, acylsulfonamide and tetrazole are optionally substituted with one or more substituents independently selected from: C1-C6 alkyl, haloalkyl and aryl-C0-4-alkyl; R2 is —H, an aliphatic group, a substituted aliphatic group, haloalkyl, an aromatic group, a substituted aromatic group, —COR4, —COOR4, —CONR5R6, —C(S)R4, —C(S)OR4 or —C(S)NR5R6.Type: ApplicationFiled: December 11, 2006Publication date: November 29, 2007Inventors: Dawn Brooks, Alan Warshawsky, Chahrzad Montrose-Rafezadeh, Anne Reifel-Miller, Lourdes Prieto, Isabel Rojo, Jose Martin, Maria Gonzales Garcia, Alicia Torrado, Rafael Crespo, Carlos Lamas-Peteira, Robert Ardecky, Maria Finger
-
Patent number: 7192982Abstract: Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, —CH2— or —CH2CH2—; W is a substituted or unsubstituted alkylene or a substituted or unsubstituted heteroalkylene linking group from two to ten atoms in length, preferably from two to seven atoms in length.Type: GrantFiled: May 30, 2002Date of Patent: March 20, 2007Assignees: Ligand Pharmaceuticals, Inc., Eli Lilly and CompanyInventors: Dawn Alisa Brooks, Alan M. Warshawsky, Chahrzad Montrose-Rafezadeh, Anne-Reifel Miller, Lourdes Prieto, Isabel Rojo, Jose Alfredo Martin, Maria Rosario Gonzales Garcia, Alicia Torrado, Rafael Ferritto Crespo, Carlos Lamas-Peteira, Robert J. Ardecky, Maria Martin-Ortega Finger
-
Publication number: 20070060585Abstract: Compounds of the general formula (I) are inhibitors of the reuptake of norepinephrine. As such, they may be useful for the treatment of disorders of the central and/or peripheral nervous system.Type: ApplicationFiled: December 10, 2004Publication date: March 15, 2007Inventors: Peter Gallagher, Carlos Lamas-Peteira, Francisco Agejas-Chicharro
-
Publication number: 20050020684Abstract: Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, —CH2— or —CH2CH2—; W is a substituted or unsubstituted alkylene or a substituted or unsubstituted heteroalkylene linking group from two to ten atoms in length, preferably from two to seven atoms in length.Type: ApplicationFiled: May 30, 2002Publication date: January 27, 2005Inventors: Dawn Brooks, Alan Warshawsky, Chahrzad Montrose-Rafezadeh, Anne-Reifel Miller, Lourdes Prieto, Isabel Rojo, Jose Alfredo Martin, Maria Rosario Gonzales Garcia, Alicia Torrado, Rafael Crespo, Carlos Lamas-Peteira, Robert Ardecky, Maria Martin-Ortega Finger
-
Patent number: 6846830Abstract: Use of compounds of the formula (I) where A, E, R1, R2, p and q have the meanings given in the specification are GluR6 antagonists useful for the treatment of disorders of the central nervous system.Type: GrantFiled: March 19, 2001Date of Patent: January 25, 2005Assignee: Eli Lilly and CompanyInventors: Stephen Richard Baker, David Bleakman, Carlos Lamas-Peteira
-
Publication number: 20050014750Abstract: This invention relates to compounds of formula (I) where R1 to R12, —W—V—, —X—Y—, p and n have the values defined in claim 1, their preparation and use as pharmaceuticals.Type: ApplicationFiled: December 6, 2002Publication date: January 20, 2005Inventors: Javier Agejas-Chicharro, Graham Timms, Andrew Williams, Nicholas Camp, Jeremy Gilmore, Ana Bueno Melendo, Carlos Lamas-Peteira
-
Publication number: 20040180883Abstract: This invention relates to compounds of formula (I) wherein R2 to R10, —X—Y—, A, —W—, n and p have the values defined in claim 1, their preparation and use as pharmaceuticals.Type: ApplicationFiled: December 12, 2003Publication date: September 16, 2004Inventors: Jeremy Gilmore, Carlos Lamas-Peteira, Maria Alicia Torrado Varela
-
Publication number: 20040122001Abstract: This invention relates to compounds of formula (I) where R1 to R12, —W—V—, —X—Y—, m and n have the values defined in claim 1, their preparation and use as pharmaceuticals.Type: ApplicationFiled: January 16, 2004Publication date: June 24, 2004Inventors: Javier Agejas-Chicharro, Ana Belen Bueno Melendo, Nicholas Paul Camp, Jeremy Gilmore, Alma Maria Jimenez-Aguado, Carlos Lamas-Peteira, Alicia Marcos-Llorente, Michael Philip Mazanetz, Carlos Montero Salgado, Graham Henry Timms, Andrew Caerwyn Williams
-
Publication number: 20030073725Abstract: Use of compounds of the formula (I) where A, E, R1, R2, p and q have the meanings given in the specification are GluR6 antagonists useful for the treatment of disorders of the central nervous system.Type: ApplicationFiled: September 16, 2002Publication date: April 17, 2003Inventors: Stephen Richard Baker, David Bleakman, Carlos Lamas-Peteira
-
Patent number: 5869691Abstract: The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided tetrahydro-beta-carboline related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.Type: GrantFiled: April 8, 1997Date of Patent: February 9, 1999Assignee: Eli Lilly and CompanyInventors: James E. Audia, Stephen Richard Baker, Jesus Ezquerra Carrera, Carlos Lamas Peteira, Concepcion Pedregal Tercero
-
Patent number: 5861410Abstract: The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided tetrahydro-beta-carboline related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.Type: GrantFiled: April 9, 1997Date of Patent: January 19, 1999Assignee: Eli Lilly and CompanyInventors: James E. Audia, Stephen Richard Baker, Jesus Ezquerra Carrera, Carlos Lamas Peteira, Concepcion Pedregal Tercero
-
Patent number: 5861409Abstract: The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided tetrahydro-beta-carboline related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.Type: GrantFiled: April 8, 1997Date of Patent: January 19, 1999Assignee: Eli Lilly and CompanyInventors: James E. Audia, Stephen Richard Baker, Jesus Ezquerra Carrera, Carlos Lamas Peteira, Concepcion Pedregal Tercero
-
Patent number: 5861408Abstract: The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided tetrahydro-beta-carboline related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.Type: GrantFiled: April 8, 1997Date of Patent: January 19, 1999Assignee: Eli Lilly and CompanyInventors: James E. Audia, Stephen Richard Baker, Jesus Ezquerra Carrera, Carlos Lamas Peteira, Concepcion Pedregal Tercero
-
Patent number: 5663178Abstract: The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided tetrahydro-beta-carboline related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.Type: GrantFiled: February 6, 1995Date of Patent: September 2, 1997Assignee: Eli Lilly and CompanyInventors: James E. Audia, Stephen Richard Baker, Jesus Ezquerra Carrera, Carlos Lamas Peteira, Concepcion Pedregal Tercero
-
Patent number: 5643916Abstract: The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided tetrahydro-beta-carboline related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.Type: GrantFiled: May 19, 1995Date of Patent: July 1, 1997Assignee: Eli Lilly and CompanyInventors: James E. Audia, Stephen Richard Baker, Jesus Ezquerra Carrera, Carlos Lamas Peteira, Concepcion Pedregal Tercero